# Concord Biotech share price today (Concord Biotech Ltd, NSE: CONCORDBIO)

> Concord Biotech share price today: ₹1,245.60 at the NSE close on 30 October 2026, down 13.7% in a year. Concord Biotech (NSE: CONCORDBIO) is worth ₹13,031 crore, trades at a P/E of 45.7 and has closed between ₹1,014.80 and ₹1,571.30 over the past 52 weeks. > Concord Biotech Ltd's results are improving, while its P/E is near the low end of its own history over 3.2 years, higher than only 26% of past readings. CONCORDBIO · Pharma - API & CRAMS · data as of 30 October 2026. Page: https://www.sectoralpha.in/stocks/concord-biotech-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: ₹1,245.60 (−13.7% in a year)
- P/E: 45.7× (lower than 74% of the last 3.2 years)
- Revenue (Sep 2026): ₹309 Cr (+25.1% on a year ago)
- Profit (Sep 2026): ₹70.0 Cr (+11.1% on a year ago)
- Operating margin: 34.0% (−2.0 points on a year ago)
- ROCE: 17%, FY26
- ROIC: 15.8%, against a 12.0% cost of capital: +3.8 points

Biggest thing to watch: the price has already been rising for 12 weeks, so timing is the risk more than the business. ## What is the Concord Biotech share price today? Concord Biotech Ltd's share price was ₹1,245.60 at the close on 30 October 2026. It has been rising for 12 weeks. That is 8.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,015 and ₹1,571, and at that close it sat 41% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 2 weeks running. Over the last 3.2 years the share price moved +32% while the NIFTY 500 moved +29%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 16 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What are Concord Biotech's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Concord Biotech reported revenue of ₹309 crore, up 25.1% from ₹247 crore a year earlier, and a profit of ₹70.0 crore, up 11.1% from ₹63.0 crore. ### Concord Biotech results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹309 crore | ₹247 crore | +25.1% |
| Profit | ₹70.0 crore | ₹63.0 crore | +11.1% |
| Earnings per share | ₹6.75 | ₹6.08 | +11.0% |
| Operating margin | 34.0% | 36.0% | −2.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Concord Biotech's management discussed these results on a call held on 28 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Concord Biotech share price history? Concord Biotech closed at ₹1,245.60 on 30 October 2026, down 13.7% from ₹1,443.80 a year earlier (31 October 2025) and up 3.4% over three years. Its highest weekly close since August 2023 was ₹2,601.10 on 20 September 2024. ### Concord Biotech share price: then and now

| When | Close | Change to 30 Oct 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,229.30 | +1.3% |
| 1 month ago · 1 Oct 2026 | ₹1,374.10 | −9.4% |
| 6 months ago · 30 Apr 2026 | ₹1,142.00 | +9.1% |
| 1 year ago · 31 Oct 2025 | ₹1,443.80 | −13.7% |
| 3 years ago · 27 Oct 2023 | ₹1,205.20 | +3.4% |
| Earliest and lowest weekly close in our records · 18 Aug 2023 | ₹942.80 | +32.1% |
| Highest weekly close since August 2023 · 20 Sep 2024 | ₹2,601.10 | −52.1% |
| 52-week high (weekly close) · 21 Aug 2026 | ₹1,571.30 | −20.7% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹1,014.80 | +22.7% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 30 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes. (172 weekly closes from 18 August 2023 to 30 October 2026.)

## What is the latest news on Concord Biotech? 4 Nov 2026: Bonus issue: 1 new share for every 1 held (ex-date). 30 Oct 2026: Concord Biotech closed at ₹1,245.60, up 1.3% on the week and down 9.4% on the month. ### Earlier

- 28 Oct 2026: Concord Biotech held its results call for July to September 2026. Management guided: FY27 revenue slightly better than 18-19%, API slightly higher with Q3 visibility. - Results for July to September 2026: Revenue up 25.1% and profit up 11.1% on a year earlier. - 24 Jul 2026: ex-date for a dividend of ₹7.55 a share. ## What dividend does Concord Biotech pay? Concord Biotech paid ₹7.55 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.61% at the ₹1,245.60 close on 30 October 2026. The last was a dividend of ₹7.55 a share, ex-date 24 July 2026. ### Concord Biotech dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 24 Jul 2026 | ₹7.55 | Dividend | same day |
| 3 Sep 2025 | ₹10.70 | Dividend | same day |
| 21 Jun 2024 | ₹8.75 | Dividend | 22 Jun 2024 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 2 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Concord Biotech Ltd paid out 30% of its profit as dividends in FY26, and it paid a dividend in 6 of its last 7 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Concord Biotech management say on the latest results call? On the call for July to September 2026, held on 28 October 2026, Concord Biotech's management guided: FY27 revenue slightly better than 18-19%, API slightly higher with Q3 visibility. > “I would say that we would continue to consider growth for this financial year to be slightly better than our historical growth of 18%.”
> Ankur Vaid, on the call for July to September 2026

### What management guided

- Operating margin 38-40% over next few years once new units ramp. - Capital spending ₹50-60 crore each in FY27-28, totalling ₹100-120 crore vs ₹20-30 crore maintenance. - Effective tax rate 24-25% for rest of FY27 and FY28. - Injectable topline around ₹300 crore over 3-4 years on ₹5,000 crore TAM. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/50287-28-Oct-2026.pdf). (From the call for July to September 2026, 28 October 2026.)

## What to watch in Concord Biotech's next results? When Concord Biotech reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Injectable contracts expected in H2 - check for signed deals and Unit 4 utilisation commentary moving up from low base. - What to check (from the call)
- Injectable contracts expected in H2 - check for signed deals and Unit 4 utilisation commentary moving up from low base. - Stellon US ramp in H2 - check tofacitinib traction and MMF oral suspension supply within flagged window. - Q3 growth delivery and input-cost normalisation - check reported growth vs above-history framing and gross pressure easing. ## Which stock lists is Concord Biotech on? Concord Biotech is on 2 of our India lists: Small & mid cap stocks and Pharma stocks. - [Small & mid cap stocks Size rank in India: 484](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 13031](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Concord Biotech profitable? Concord Biotech Ltd earned ₹70.0 Cr of net profit in the Sep 2026 quarter, +11.1% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹259 Cr. Over 6 years profit has grown 7.4% a year on average. That is 22.7% of the quarter's revenue. The same quarter a year earlier earned ₹63.0 Cr. For the full year, FY26 profit was ₹259 Cr (−30.4% on the year before). Why profit moved: revenue changed +25.1% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −2.5% and revenue +10.2%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Concord Biotech make, and is it growing? Concord Biotech Ltd reported ₹309 Cr of revenue in the Sep 2026 quarter, +25.1% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 6 years it has grown 12.8% a year on average. The last full year, FY26, came in at ₹1,055 Cr. The last four reported quarters add to ₹1,170 Cr. FY26 revenue was ₹1,055 Cr, −12.1% on the year before. Recent pace: the last four quarters grew +10.2% on average, against 12.8% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +4.0%, against +3.8% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −13.3%, against −7.7% a year (rolling over). ## How much of every ₹100 of sales does Concord Biotech keep? Concord Biotech Ltd's operating margin was 34.0% in the Sep 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 7 years it has been between 35.0% and 53.0%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −2.3 percentage points on the year while gross margin changed −4.3 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Concord Biotech's profit turning into cash? Over the last 3 years, 83% of Concord Biotech Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹267 Cr of operating cash against ₹259 Cr of profit. After ₹96.0 Cr of spending on assets, ₹171 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 83% of profit came in as cash: the cash cycle got 37 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 1.6× depreciation over three years. The next section checks what that spending is building. ## Where does Concord Biotech's cash go? Concord Biotech Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 493 days in FY26, up from 456 days in FY21. It spent ₹284 Cr on assets over the last 3 years. Customers take 159 days to pay, and stock sits for 485 days on average. At FY26 sales of ₹1,055 Cr, each day of that cycle ties up about ₹2.9 Cr, so roughly ₹1,425 Cr is tied up in the business at any time. FY26: customers took 159 days to pay and stock sat for 485 days, about 16.0 months of sales sitting as stock, for a full cycle of 493 days, longer than FY21's 456. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 485 days. Customers pay about 159 days after that. Suppliers are paid at 151 days. Together that makes the 493-day cycle. Spending on assets: ₹284 Cr over the last 3 years, against ₹182 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹79.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Concord Biotech's P/E ratio, and how does it compare with its own history? Concord Biotech Ltd's P/E is 45.7×, near the low end of its own history: it has been lower only 26% of the time. Its usual P/E (the middle reading) is 51.8×, over 3.2 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹26.99. Why the multiple is where it is: over the past year earnings per share moved −29.8% while the price moved −13.7%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved +1.1% a year; about +6.3% a year came from earnings growth and about −5.2 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Concord Biotech business getting better or worse? Concord Biotech Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −13.3% in the latest quarter, against +28.9% at its best in 12 quarters, with ROCE falling at 18.7%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Concord Biotech earn on its capital? Concord Biotech Ltd earned a ROCE of 17% in FY26. Its return on capital used (ROIC) is 3.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 24.5% net margin and 0.47× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 24.5% net margin × 0.47× asset turnover × 1.11× leverage (assets divided by equity) ≈ 12.8% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 15.8% − 12.0% = +3.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. ## Does Concord Biotech have too much debt? Concord Biotech Ltd has total debt of ₹2.0 Cr against shareholder equity of ₹2,072 Cr as of Sep 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.02 in FY23 to 0.00 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Concord Biotech shareholding pattern? Domestic institutions raised their stake in Concord Biotech Ltd by 1.1 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 10.9% of the company. Foreign institutions moved −0.8 points over the same period, to 7.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +1.1 points over 8 quarters, to 10.9%; Foreign institutions: −0.8 points over 8 quarters, to 7.3%; Promoters: +0.0 points over 8 quarters, to 44.1%. Why the owners changed: domestic institutions drove it (+1.1 points), with the other side taken by foreign institutions (−0.8 points). They raised their stake step by step. ## How far is Concord Biotech from balance-sheet trouble? For Concord Biotech Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Concord Biotech rank in its industry? 40.8 out of 100, rank 18 of 24 in Pharma - API & CRAMS, with 85% of the evidence available. Concord Biotech Ltd scores 40.8 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 18. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 7.8 + 15.6 + 8.3 + 9.1 = 40.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Concord Biotech compared with? Concord Biotech ranks 18 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 40.8 out of 100. 1. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) NEULANDLAB · leader · Most evidence points up · 96% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.3/35 · Revenue 78.3% · Profit 100% · Operating margin change 23 points · 88% evidence Capital efficiency 22.9/25 · ROCE 26.5% · Operating margin 35% · 100% evidence Valuation 14.1/20 · P/E 50.8× · PEG 1.04 · 100% evidence Relative strength 6.7/20 · Lead over its industry -7.8% · Lead over NIFTY 500 20.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.3 + 22.9 + 14.1 + 6.7 = 76 · What this means: Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. 2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ACUTAAS · turning · Most evidence points up · 67% evidence 73.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.3/25 · ROCE 31.6% · Operating margin 40% · 76% evidence Valuation 10.2/20 · P/E 74.6× · PEG n/a · 50% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 59.6% · 1 year 131.7% · 25% evidence · 2 of 9 weeks ahead Exact sum: 31.3 + 20.3 + 10.2 + 12.1 = 73.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) LAURUSLABS · leader · Most evidence points up · 93% evidence 71.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.3/25 · ROCE 17.8% · Operating margin 34% · 100% evidence Valuation 5.8/20 · P/E 97× · PEG 2.98 · 65% evidence Relative strength 17.0/20 · Lead over its industry 42.3% · Lead over NIFTY 500 82.8% · 1 year 152.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.9 + 17.3 + 5.8 + 17 = 71 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 96% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 17.6% · Profit 46.4% · Operating margin change 3 points · 88% evidence Capital efficiency 16.0/25 · ROCE 15.1% · Operating margin 27% · 100% evidence Valuation 12.1/20 · P/E 44.6× · PEG 1.45 · 100% evidence Relative strength 16.8/20 · Lead over its industry 15.1% · Lead over NIFTY 500 49.3% · 1 year 60.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25 + 16 + 12.1 + 16.8 = 69.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 100% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.3% · Operating margin 14% · 100% evidence Valuation 13.9/20 · P/E 24.6× · PEG 0.66 · 100% evidence Relative strength 13.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 53.8% · 1 year 92.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.1 + 12.8 + 13.9 + 13.9 = 69.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Most evidence points up · 89% evidence 67.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 28% · Profit 100% · Operating margin change 1 points · 88% evidence Capital efficiency 10.8/25 · ROCE 10.9% · Operating margin 29% · 100% evidence Valuation 9.9/20 · P/E 65.7× · PEG 1.73 · 65% evidence Relative strength 19.9/20 · Lead over its industry 47.2% · Lead over NIFTY 500 84.2% · 1 year 170.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.4 + 10.8 + 9.9 + 19.9 = 67 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) MOREPENLAB · leader · Evidence leans up · 85% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% · Operating margin 16% · 100% evidence Valuation 8.5/20 · P/E 32.9× · PEG 2.14 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 94.5% · 1 year 139% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 8.5 + 12.5 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Evidence leans up · 96% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 16.4% · Profit 26.8% · Operating margin change 11 points · 88% evidence Capital efficiency 18.6/25 · ROCE 22% · Operating margin 41% · 100% evidence Valuation 2.6/20 · P/E 87.1× · PEG 3.45 · 100% evidence Relative strength 15.5/20 · Lead over its industry 9.2% · Lead over NIFTY 500 43.1% · 1 year 45.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.7 + 18.6 + 2.6 + 15.5 = 61.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 9. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · turning · Evidence leans up · 96% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 24.8% · Profit 38.1% · Operating margin change 3 points · 88% evidence Capital efficiency 16.2/25 · ROCE 15.5% · Operating margin 23% · 100% evidence Valuation 10.2/20 · P/E 35.2× · PEG 1.29 · 100% evidence Relative strength 6.7/20 · Lead over its industry -5.2% · Lead over NIFTY 500 24.2% · 1 year 48.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.3 + 16.2 + 10.2 + 6.7 = 57.4 · What this means: Earnings are strong; relative strength in its sector is -5.2% and the one-year return is 48.5%. 10. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) SAILIFE · leader · Evidence leans up · 89% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 17.6% · Profit 48% · Operating margin change 3 points · 88% evidence Capital efficiency 17.0/25 · ROCE 19.6% · Operating margin 27% · 100% evidence Valuation 4.8/20 · P/E 90× · PEG 3.63 · 65% evidence Relative strength 13.8/20 · Lead over its industry 9.9% · Lead over NIFTY 500 42.9% · 1 year 69.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.7 + 17 + 4.8 + 13.8 = 57.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) SMSPHARMA · breaking out · Evidence leans up · 96% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) BLUEJET · quiet · Evidence leans up · 81% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) SOLARA · breaking out · Evidence leans down · 74% evidence 49.5 out of 100 Growth Capital Valuation Relative
14. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) WINDLAS · leader · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
15. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · leader · Evidence leans down · 89% evidence 46.7 out of 100 Growth Capital Valuation Relative
16. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) PPLPHARMA · leader · Evidence leans down · 71% evidence 44.6 out of 100 Growth Capital Valuation Relative
17. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) SUPRIYA · breaking out · Evidence leans down · 96% evidence 43.7 out of 100 Growth Capital Valuation Relative
18. Concord Biotech Ltd this page CONCORDBIO · quiet · Evidence leans down · 85% evidence 40.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 7.8/35 · Revenue 4% · Profit -13.3% · Operating margin change -2 points · 100% evidence Capital efficiency 15.6/25 · ROCE 17.1% · Operating margin 34% · 100% evidence Valuation 8.3/20 · P/E 45.7× · PEG 5.67 · 100% evidence Relative strength 9.1/20 · Lead over its industry n/a · Lead over NIFTY 500 1.8% · 1 year -13.7% · 25% evidence · 10 of 12 weeks ahead Exact sum: 7.8 + 15.6 + 8.3 + 9.1 = 40.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 19. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) JUBLPHARMA · turning · Most evidence points down · 86% evidence 30.3 out of 100 Growth Capital Valuation Relative
20. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Most evidence points down · 78% evidence 29.7 out of 100 Growth Capital Valuation Relative
21. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ONESOURCE · turning · Most evidence points down · 83% evidence 29.2 out of 100 Growth Capital Valuation Relative
22. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) SYNGENE · turning · Most evidence points down · 100% evidence 27.8 out of 100 Growth Capital Valuation Relative
23. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) COHANCE · breaking out · Most evidence points down · 78% evidence 27.1 out of 100 Growth Capital Valuation Relative
24. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) DCAL · basing · Most evidence points down · 64% evidence 27.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to Concord Biotech in size? Concord Biotech is the 15th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Cohance Lifesciences, Syngene International and Jubilant Pharmova. Just below it: Blue Jet Healthcare, Supriya Lifescience and Morepen Laboratories. ### Pharma - API & CRAMS companies close in size

1. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) ₹16,999 crore
2. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) ₹16,256 crore
3. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) ₹14,716 crore
4. Concord Biotech Ltd ₹13,031 crore
5. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) ₹9,550 crore
6. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) ₹6,819 crore
7. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) ₹6,211 crore

[All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies)

### Companies close in size in other industries

1. [Gujarat Mineral Development Corporation Ltd](https://www.sectoralpha.in/stocks/gujarat-mineral-development-corporation-ltd) ₹13,090 crore · Mining/Minerals
2. [Fractal Analytics Ltd](https://www.sectoralpha.in/stocks/fractal-analytics-ltd) ₹13,059 crore · IT Enabled Services/Business Process Outsourcing
3. Concord Biotech Ltd ₹13,031 crore
4. [Anupam Rasayan India Ltd](https://www.sectoralpha.in/stocks/anupam-rasayan-india-ltd) ₹13,019 crore · Speciality Chemicals
5. [Godawari Power & Ispat Ltd](https://www.sectoralpha.in/stocks/godawari-power-ispat-ltd) ₹12,987 crore · Mining/Minerals - Iron Ore

## What else do people ask about Concord Biotech? ### What were Concord Biotech's latest quarterly results? Concord Biotech Ltd reported revenue of ₹309 Cr and net profit of ₹70.0 Cr for the Sep 2026 quarter. Revenue rose 25.1% and profit rose 11.1% compared with a year earlier. Earnings per share were ₹6.75. The operating margin was 34.0%, 2.0 percentage points lower than a year earlier (as of 30 October 2026). ### What is Concord Biotech's market cap? Concord Biotech Ltd's market capitalisation is ₹13,031 Cr at a share price of ₹1,245.60. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 30 October 2026). ### How is Concord Biotech performing? Concord Biotech Ltd's share price has been rising for 12 weeks. In its latest quarter, revenue rose 25.1% and profit rose 11.1% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 2 weeks running (as of 30 October 2026). ### Will Concord Biotech's share price go up? This page does not forecast Concord Biotech Ltd's share price. What it shows instead: the share price is ₹1,245.60, and it has been rising for 12 weeks. Its P/E of 45.7× is higher than 26% of its own last 3 years (as of 30 October 2026). ### Who owns Concord Biotech? Promoters own 44.1% of Concord Biotech Ltd, foreign institutions 7.3%, domestic institutions 10.9% and the public 37.7% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 1.1 percentage points over 8 quarters (as of 30 October 2026). ### Does Concord Biotech have too much debt? No, Concord Biotech Ltd has little debt: its debt is 0.00× its equity, and its operating profit is more than 100 times its interest bill. FY26 borrowings were ₹2.0 Cr against equity of ₹2,017 Cr. So the returns on this page come from the business, not borrowed money (as of 30 October 2026). ### Where is Concord Biotech in its business cycle? Concord Biotech Ltd's FY26 operating margin was 35.0%, against a 7-year range of 35.0% to 53.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 34.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 30 October 2026). ### What could break the Concord Biotech story? Biggest thing to watch: the price has already been rising for 12 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 30 October 2026). ### Is Concord Biotech a stock worth studying right now? What the numbers show: Concord Biotech Ltd's results are improving, while its P/E is near the low end of its own history over 3.2 years, higher than only 26% of past readings. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 30 October 2026). ### Is there a Concord Biotech share price forecast for 2026? What management itself guided: FY27 revenue slightly better than 18-19%, API slightly higher with Q3 visibility. ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.